Abstract：
Paclitaxel, a rare diterpene extracted from the bark of Chinese yew (Taxus chinensis), is renowned for its anti-cancer activity and serves as a primary drug for treating cancers. Due to the exceptionally low content of paclitaxel in the bark, a semi-synthetic method that depletes Chinese yew resources is used in the production of paclitaxel, which, however, fails to meet the escalating clinical demand. In recent years, researchers have achieved significant progress in heterologous biosynthesis and metabolic engineering for the production of paclitaxel. This article comprehensively reviews the advancements in paclitaxel production, encompassing chemical synthesis, heterologous biosynthesis, and cell engineering. It provides an in-depth introduction to the biosynthetic pathway and transcriptional regulation mechanisms of paclitaxel, aiming to provide a valuable reference for further research on paclitaxel biosynthesis.
摘要：
紫杉醇,一种从红豆杉树皮中提取的稀有二萜，以其抗癌活性而闻名，并作为治疗癌症的主要药物。由于树皮中紫杉醇的含量异常低，在紫杉醇的生产中使用了一种消耗红豆杉资源的半合成方法，which,然而,无法满足不断升级的临床需求。近年来,研究人员在生产紫杉醇的异源生物合成和代谢工程方面取得了重大进展。本文全面综述了紫杉醇生产的进展，包括化学合成，异源生物合成，和细胞工程。深入介绍了紫杉醇的生物合成途径和转录调控机制,旨在为紫杉醇生物合成的进一步研究提供有价值的参考。
